92 related articles for article (PubMed ID: 23146567)
1. Clinical management of small-cell carcinoma of the urinary tract: a 10-year single-center's experience.
Carranza OE; Castañón E; Abella LE; Zudaire ME; Castillo A; Arévalo E; Fusco JP; Zudaire JJ; Carías R; Cambeiro M; Martínez-Monge R; Gil-Bazo I
Clin Genitourin Cancer; 2013 Jun; 11(2):168-74. PubMed ID: 23146567
[TBL] [Abstract][Full Text] [Related]
2. [Pre-treatment and treatment-induced neuron-specific enolase in patients with small-cell lung cancer: an open prospective study].
Emin Erbaycu A; Gunduz A; Batum O; Zeren Ucar Z; Tuksavul F; Zeki Guclu S
Arch Bronconeumol; 2010 Jul; 46(7):364-9. PubMed ID: 20537457
[TBL] [Abstract][Full Text] [Related]
3. ProGRP and NSE in therapy monitoring in patients with small cell lung cancer.
Wójcik E; Kulpa JK; Sas-Korczyńska B; Korzeniowski S; Jakubowicz J
Anticancer Res; 2008; 28(5B):3027-33. PubMed ID: 19031951
[TBL] [Abstract][Full Text] [Related]
4. Small cell carcinoma of bladder: a single-center prospective study of 25 cases treated in analogy to small cell lung cancer.
Bex A; Nieuwenhuijzen JA; Kerst M; Pos F; van Boven H; Meinhardt W; Horenblas S
Urology; 2005 Feb; 65(2):295-9. PubMed ID: 15708041
[TBL] [Abstract][Full Text] [Related]
5. [Small cell carcinoma of the prostate. Description of a case].
Candura SM; Fonte R; Cantale G; Paolotti D; Biscaldi G
Recenti Prog Med; 2000 Nov; 91(11):567-70. PubMed ID: 11125949
[TBL] [Abstract][Full Text] [Related]
6. Significance of neuron-specific enolase levels before and during therapy for small cell lung cancer.
Bonner JA; Sloan JA; Rowland KM; Klee GG; Kugler JW; Mailliard JA; Wiesenfeld M; Krook JE; Maksymiuk AW; Shaw EG; Marks RS; Perez EA
Clin Cancer Res; 2000 Feb; 6(2):597-601. PubMed ID: 10690544
[TBL] [Abstract][Full Text] [Related]
7. [Combined small-cell carcinoma/adenocarcinoma of prostate: report of two cases].
Sakuma T; Yoshida T; Ohashi H; Nishimura K; Kawano K
Hinyokika Kiyo; 2007 Jul; 53(7):489-92. PubMed ID: 17702184
[TBL] [Abstract][Full Text] [Related]
8. Evaluation of neuron-specific enolase, tissue polypeptide antigen, and carcinoembryonic antigen as markers for staging and monitoring response to therapy of lung cancer.
Spinazzi A; Soresi E; Boffi R; Nonis A; Noseda A; Cobelli S; Scanni A
Cancer Detect Prev; 1994; 18(3):209-20. PubMed ID: 8076383
[TBL] [Abstract][Full Text] [Related]
9. Pro-gastrin-releasing peptide (ProGRP) and neuron specific enolase (NSE) in therapy control of patients with small-cell lung cancer.
Schneider J; Philipp M; Salewski L; Velcovsky HG
Clin Lab; 2003; 49(1-2):35-42. PubMed ID: 12593474
[TBL] [Abstract][Full Text] [Related]
10. Significance of serum neuron-specific enolase as a predictor of relapse of small cell lung cancer.
Nitta T; Fukuoka M; Masuda N; Kusunoki Y; Matsui K; Kudoh S; Hirashima T; Yana T; Ito K; Takada M
Jpn J Clin Oncol; 1995 Oct; 25(5):179-83. PubMed ID: 7474404
[TBL] [Abstract][Full Text] [Related]
11. Chromogranin A and neuron-specific enolase as prognostic markers in patients with advanced pNET treated with everolimus.
Yao JC; Pavel M; Phan AT; Kulke MH; Hoosen S; St Peter J; Cherfi A; Öberg KE
J Clin Endocrinol Metab; 2011 Dec; 96(12):3741-9. PubMed ID: 21994954
[TBL] [Abstract][Full Text] [Related]
12. [Neuron-specific enolase (NSE) and squamous cell carcinoma antigen (SCC) as serum markers in the diagnosis of bronchial carcinoma].
Lorenz J; Gillmann-Blum D; Jensen M; Kreienberg R
Pneumologie; 1990 Nov; 44(11):1259-63. PubMed ID: 2177891
[TBL] [Abstract][Full Text] [Related]
13. [Neuron-specific enolase (NSE) serum level as a prognostic factor in non-small cell lung cancer].
Zych J; Szturmowicz M; Sakowicz A; Słodkowska J; Załeska M; Radzikowska E; Załeska J; Jodkiewicz Z; Rowińska-Zakrzewska E
Pneumonol Alergol Pol; 2002; 70(5-6):278-83. PubMed ID: 12518626
[TBL] [Abstract][Full Text] [Related]
14. Genitourinary small cell carcinoma: determination of clinical and therapeutic factors associated with survival.
Mackey JR; Au HJ; Hugh J; Venner P
J Urol; 1998 May; 159(5):1624-9. PubMed ID: 9554367
[TBL] [Abstract][Full Text] [Related]
15. [Evaluation of tumor markers in the management of small cell lung cancer].
Ariyoshi Y
Gan To Kagaku Ryoho; 1988 Apr; 15(4 Pt 2-1):959-65. PubMed ID: 2839115
[TBL] [Abstract][Full Text] [Related]
16. Extrapulmonary small cell carcinoma: single center experience with 61 patients.
Lee SS; Lee JL; Ryu MH; Chang HM; Kim TW; Kim WK; Lee JS; Jang SJ; Khang SK; Kang YK
Acta Oncol; 2007; 46(6):846-51. PubMed ID: 17653910
[TBL] [Abstract][Full Text] [Related]
17. [Clinical evaluation of serum NSE (neuron specific enolase) levels in cases of small cell lung cancer].
Moriya H; Hisa S; Satoh T; Suzuki S; Kimura K; Higuchi Y; Hoshi K
Rinsho Hoshasen; 1988 Jan; 33(1):31-4. PubMed ID: 2835529
[No Abstract] [Full Text] [Related]
18. Plasma neuroendocrine markers in patients with benign prostatic hyperplasia and prostatic carcinoma.
Cussenot O; Villette JM; Valeri A; Cariou G; Desgrandchamps F; Cortesse A; Meria P; Teillac P; Fiet J; Le Duc A
J Urol; 1996 Apr; 155(4):1340-3. PubMed ID: 8632569
[TBL] [Abstract][Full Text] [Related]
19. Comparison of changes in the NSE levels with clinical assessment in the therapy monitoring of patients with SCLC.
Ebert W; Muley T; Trainer C; Dienemann H; Drings P
Anticancer Res; 2002; 22(2B):1083-9. PubMed ID: 12168905
[TBL] [Abstract][Full Text] [Related]
20. [Usefulness of monitoring levels of carcinoembryonic antigen, neuron-specific enolase and ferritin in serum of patients with small cell lung cancer for evaluating treatment outcome].
Szturmowicz M; Rogińska E; Roszkowski K; Kwiek S; Filipecki S; Rowińska-Zakrzewska E
Pneumonol Alergol Pol; 1993; 61(9-10):489-95. PubMed ID: 8111325
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
